Camber Pharmaceuticals said it recalled some of its pneumonia medicine after it discovered the drug may be  contaminated with the Bacillus cereus bacteria, according to a U.S. Food and Drug Administration (FDA) announcement.
The voluntary recall impacts one lot of Atovaquone Oral Suspension, USP in either 750-milligram or 5-milliliter doses to the consumer level due to possible contamination, the March 31 announcement said. The drug is meant to prevent and treat  pneumonia caused by Pneumocystis jiroveci, a type of fungus that can cause infections, in adults and teens who can’t tolerate other drugs.
“In the population most at risk, immunocompromised population, there is a reasonable probability that microbial contamination of Atovaquone Oral Suspension can result in disseminated, life threatening infections such as endocarditis and necrotizing soft tissue infections,” the notice said….